Association for Molecular Pathology v. Myriad Genetics, Inc.
Supreme Court of the United States
1Opinion of the CourtJustice Thomas
*579 Respondent Myriad Genetics, Inc. (Myriad), discovered the precise location and *2111 sequence of two human genes, mutations *580 of which can substantially increase the risks of breast and ovarian cancer. Myriad obtained a number of patents based upon its discovery. This case involves claims from three of them and requires us to resolve whether a naturally occurring segment of deoxyribonucleic acid (DNA) is patent eligible under 35 U.S.C. § 101 by virtue of its isolation from the rest of the human genome. We also address the patent eligibility of synthetically created DNA known as complementary DNA…
Also in this document: Concurring in the judgment.
2Cases cited10 opinions
- MedImmune, Inc. v. Genentech, Inc.Supreme Court of the United States · 2007
- Mayo Collaborative Services v. Prometheus Laboratories, Inc.Supreme Court of the United States · 2012
- Diamond v. ChakrabartySupreme Court of the United States · 1980
- Hartranft v. WiegmannSupreme Court of the United States · 1887
- J. E. M. Ag Supply, Inc. v. Pioneer Hi-Bred International, Inc.Supreme Court of the United States · 2001
5 more not listed; retrieve them via the Exa API.
3Cited by356 opinions
- Enfish, LLC v. Microsoft CorporationCourt of Appeals for the Federal Circuit · 2016
- Halo Electronics, Inc. v. Pulse Electronics, Inc.Supreme Court of the United States · 2016
- BASCOM Global Internet Services, Inc. v. AT&T Mobility LLCCourt of Appeals for the Federal Circuit · 2016
- McRO, Inc. v. Bandai Namco Games America Inc.Court of Appeals for the Federal Circuit · 2016
- Tli Communications LLC v. Av Automotive, L.L.C.Court of Appeals for the Federal Circuit · 2016
351 more not listed; retrieve them via the Exa API.